TerminatedNot Applicable

Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

Stopped: Terminated due to lack of recruitment and difficulty in the selection of sites

France3 participantsStarted 2014-07

Plain-language summary

The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of growth hormone deficiency proven by appropriate exploration
✓. Size ≤ -2 Standard Deviation (SD) according to the French references
✓. Growth velocity in the previous year inferior to the normal for age (-1SD) or \< 4cm/year
✓. Turner's syndrome confirmed by a karyotype
✓. Patient's size ≤ -2 SD according to the French references
✓. Bone age \< 12 years

What they're measuring

Rate of overall treatment adherence

Timeframe: Up to 18 months

Trial details

NCT IDNCT02018172

SponsorFerring Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-02

View on ClinicalTrials.gov More Growth Hormone Deficiency trials